Drug Profile
Research programme: focal adhesion kinase inhibitors - Novartis
Alternative Names: NVP-TAE 226; TAE 226Latest Information Update: 22 May 2012
Price :
$50
*
At a glance
- Originator Novartis
- Class Benzamides; Pyrimidines; Small molecules
- Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 22 May 2012 No development reported - Preclinical for Cancer in Japan (PO)
- 15 Sep 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2009)
- 24 Oct 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)